Last 12 months
Inside the activity.
1 purchase rows · 24 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 2 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,727 | $28.69 | $135,617.63 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 9 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 484,872 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.135 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 1,273 | $29.32 | $37,324.36 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 483,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.16 to $29.73 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,727 | $28.69 | $135,617.63 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 484,872 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.135 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:20 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 23,346 | $29.18 | $681,308.65 |
DisclosureSEC source: 0001387131-20-008752 · pgny-form4_100120.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 16,920,328 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.95 to $29.89 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 16,885,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 16:20 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 46,444 | $28.62 | $1,329,357.32 |
DisclosureSEC source: 0001387131-20-008752 · pgny-form4_100120.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 16,943,674 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.18 to $28.94 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 16,885,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 23:19 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 4,965 | $29.37 | $145,822.05 |
DisclosureSEC source: 0001209191-20-053894 · doc4.xml · nonDerivative · entry 2 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 420,010 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.22 to $29.89 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 23:19 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 35,035 | $28.64 | $1,003,402.40 |
DisclosureSEC source: 0001209191-20-053894 · doc4.xml · nonDerivative · entry 1 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 424,975 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $29.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7) and (8) herein. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,438 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · derivative · entry 6 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,001 Underlying: Common Stock · 3,438 shares Expires 2029-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on May 23, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 633 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · derivative · entry 5 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,975 Underlying: Common Stock · 633 shares Expires 2029-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on March 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
SaleCommon Stock | 1,803 | $29.98 | $54,053.94 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · nonDerivative · entry 4 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,731 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 15, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.98 to $29.994 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
Tax withholdingCommon Stock | 2,268 | $30.04 | $68,130.72 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · nonDerivative · entry 3 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,534 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
Exercise / conversionCommon Stock | 3,438 | $3.96 | $13,614.48 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · nonDerivative · entry 2 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 19:45 UTC |
Bealer JenniferEVP, General Counsel
|
Exercise / conversionCommon Stock | 633 | $3.96 | $2,506.68 |
DisclosureSEC source: 0001209191-20-052776 · doc4.xml · nonDerivative · entry 1 Bealer Jennifer · CIK 0001789513 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · derivative · entry 12 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,002 Underlying: Common Stock · 4,000 shares Expires 2029-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on June 3, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
SaleCommon Stock | 1,772 | $30.03 | $53,213.16 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 9 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,044 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 22, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.026 to $30.035 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Tax withholdingCommon Stock | 2,228 | $30.04 | $66,929.12 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 8 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,816 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionCommon Stock | 4,000 | $3.96 | $15,840.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 7 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 54 | $30.02 | $1,621.08 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 638,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.02 to $30.05 inclusive. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,446 | $29.42 | $130,801.32 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 638,054 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.94 to $29.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7) and (8) herein. F6 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 73 | $30.02 | $2,191.46 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 489,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.02 to $30.05 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,927 | $29.42 | $174,372.34 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 489,672 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.94 to $29.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7) and (8) herein. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 73 | $30.02 | $2,191.46 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 489,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.02 to $30.05 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 22:09 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,927 | $29.42 | $174,372.34 |
DisclosureSEC source: 0001209191-20-053328 · doc4.xml · nonDerivative · entry 1 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 489,672 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.94 to $29.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (7) and (8) herein. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:07 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 3,324 | $29.51 | $98,091.24 |
DisclosureSEC source: 0001209191-20-052401 · doc4.xml · nonDerivative · entry 4 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 460,010 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $29.73 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:07 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 8,131 | $29.00 | $235,799.00 |
DisclosureSEC source: 0001209191-20-052401 · doc4.xml · nonDerivative · entry 3 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 463,334 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.40 to $29.39 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| September 29, 2020 Filed Oct 1, 2020 23:44 UTC |
Anevski PeterPresident and COO
|
SaleCommon Stock | 84,000 | $29.30 | $2,461,200.00 |
DisclosureSEC source: 0001209191-20-052775 · doc4.xml · nonDerivative · entry 1 Anevski Peter · CIK 0001576147 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 336,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.02 to $29.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reportable securities are held directly by the PECO ANEVSKI 2020 SD LLC (the "LLC"). Read SEC document |
| September 28, 2020 Filed Sep 29, 2020 16:54 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 7,447 | $28.48 | $212,061.52 |
DisclosureSEC source: 0001387131-20-008563 · ownership.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 16,990,118 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.14 to $28.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 16,990,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 00:07 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 26,331 | $28.54 | $751,486.74 |
DisclosureSEC source: 0001209191-20-052401 · doc4.xml · nonDerivative · entry 2 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 471,465 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $29.19 inclusive. F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 16:54 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 68,273 | $28.56 | $1,949,801.78 |
DisclosureSEC source: 0001387131-20-008563 · ownership.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 16,997,565 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.13 to $29.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 16,990,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 25, 2020 Filed Sep 29, 2020 16:54 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 6,668 | $27.82 | $185,531.77 |
DisclosureSEC source: 0001387131-20-008563 · ownership.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 17,065,838 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.12 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 16,990,118 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F6 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F7 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 25, 2020 Filed Sep 30, 2020 00:07 UTC |
Schlanger David JDirector · Chief Executive Officer
|
SaleCommon Stock | 40,000 | $28.40 | $1,136,000.00 |
DisclosureSEC source: 0001209191-20-052401 · doc4.xml · nonDerivative · entry 1 Schlanger David J · CIK 0001576145 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 497,796 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5) and (6). F3 · ownership.nature: The reportable securities are held directly by the David J. Schlanger 2020 SD LLC. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 16:18 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 50,661 | $27.39 | $1,387,650.38 |
DisclosureSEC source: 0001387131-20-008488 · pgny-form4_092320.xml · nonDerivative · entry 4 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 17,072,506 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.70 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 17,072,506 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 16:18 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 10,423 | $26.88 | $280,177.54 |
DisclosureSEC source: 0001387131-20-008488 · pgny-form4_092320.xml · nonDerivative · entry 3 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 17,123,167 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.51 to $27.10 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 17,072,506 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 82 | $27.68 | $2,269.76 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 12 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 642,500 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.695 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,418 | $27.32 | $120,699.76 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 11 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 642,582 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 to $27.65 inclusive. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 109 | $27.68 | $3,017.12 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 10 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 495,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.695 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,891 | $27.32 | $160,942.12 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 9 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 495,708 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 to $27.65 inclusive. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 109 | $27.68 | $3,017.12 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 8 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 495,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.695 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| September 24, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,891 | $27.32 | $160,942.12 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 7 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 495,708 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.66 to $27.65 inclusive. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
| September 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · derivative · entry 11 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,002 Underlying: Common Stock · 2,000 shares Expires 2029-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the Option vested on June 3, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the Option vested or shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| September 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
SaleCommon Stock | 869 | $26.77 | $23,263.13 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 6 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,044 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on June 22, 2020. Read SEC document |
| September 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Tax withholdingCommon Stock | 1,131 | $26.73 | $30,231.63 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 5 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,913 Read SEC document |
| September 24, 2020 Filed Oct 1, 2020 23:43 UTC |
Greenbaum LisaEVP, Chief Client Officer
|
Exercise / conversionCommon Stock | 2,000 | $3.96 | $7,920.00 |
DisclosureSEC source: 0001209191-20-052774 · doc4.xml · nonDerivative · entry 4 Greenbaum Lisa · CIK 0001791866 · EVP, Chief Client Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 16:18 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 60,188 | $27.30 | $1,642,831.46 |
DisclosureSEC source: 0001387131-20-008488 · pgny-form4_092320.xml · nonDerivative · entry 2 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 17,133,590 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 to $27.57 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 17,072,506 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 16:18 UTC |
BONDERMAN DAVID10% owner
COULTER JAMES G10% owner
|
SaleCommon Stock | 29,328 | $26.91 | $789,151.96 |
DisclosureSEC source: 0001387131-20-008488 · pgny-form4_092320.xml · nonDerivative · entry 1 TPG Group Holdings (SBS) Advisors, Inc. · CIK 0001495741 · 10% owner BONDERMAN DAVID · CIK 0000860866 · 10% owner COULTER JAMES G · CIK 0001099776 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 17,193,778 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by TPG Biotech III. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F1 · ownership.nature: David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotechnologies GenPar III Advisors, LLC, which is the general partner of TPG Biotechnology GenPar III, L.P., which is the general partner of TPG Biotechnology Partners III, L.P. ("TPG Biotech III"), which directly holds 17,072,506 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Progyny, Inc. (the "Issuer"). F7 · ownership.nature: Because of the relationship between the Reporting Persons and TPG Biotech III, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech III. Each of TPG Biotech III and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech III's or such Reporting Person's pecuniary interest therein, if any. F8 · ownership.nature: Pursuant to Rule 16a-1(a)(4) under the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 28 | $27.55 | $771.40 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 6 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 647,000 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 4,472 | $27.08 | $121,101.76 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 5 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 647,028 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6) and (7) herein. F5 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Melinda B. Payson, Trustees of The Norman C. and Melinda B. Payson Revocable Trust ("NMP Trust"). Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 36 | $27.55 | $991.80 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 4 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 501,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 5,964 | $27.08 | $161,505.12 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 3 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 501,635 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (6) and (7) herein. F4 · ownership.nature: The reportable securities are directly held by Norman C. Payson and Robert L. Carson, Trustee of The Norman C. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("NCP GRAT"). The Reporting Person is a trustee of the NCP GRAT. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 21:05 UTC |
Payson NormanDirector
|
SaleCommon Stock | 36 | $27.55 | $991.80 |
DisclosureSEC source: 0001209191-20-052108 · doc4.xml · nonDerivative · entry 2 Payson Norman · CIK 0000898544 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 501,599 F1 · kind: Shares sold pursuant to a Rule 10b5-1 trading plan entered into on March 11, 2020. F3 · ownership.nature: The reportable securities are directly held by Melinda B. Payson and Robert L. Carson, Trustee of The Melinda B. Payson 2018 Grantor Retained Annuity Trust dated November 28, 2018 ("MBP GRAT"). The Reporting Person's spouse is a trustee of the MBP GRAT. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.